EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 6M’18 6M’19 change Q2’18 Q1’19 Q2’19 change change Btmn Btmn y-on-y Btmn Btmn Btmn y-on-y q-on-q Sales and service income 16,961 21,123 24.5% 8,805 10,257 10,866 23.4
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 30 September 2017 2018 THB mm % THB mm % THB mm % Sale Revenue Revenue from selling product under Company’s trademark 1
–2021 Balance by Quarter Change Q2–21 Q1–21 Q2–20 Q2–21 VS Q1–21 Q2–21 VS Q2–20 (Million Baht: MB) (MB) % (MB) % Total revenue 2,081.2 1,824.2 1,187.6 257.0 14.1 893.6 75.2 Total operating expenses
ควำมเสี่ยงที่ตนเองยอมรับได้ (2.4) ผู้แสดงควำมคิดเห็นไม่เห็นด้วยกรณีที่ลูกค้ำปฏิเสธกำรให้ข้อมูล ท ำให้ไม่สำมำรถท ำ suitability test ได้ ให้ผู้ประกอบธุรกิจปฏิเสธกำรให้บริกำรนั้น และหำกผล suitability test
transactions; (b) presenting capital market products or services suitable for clients based on the results of the clients’ suitability test and recommended asset allocation; (c) distributing documents for
) presenting capital market products or services suitable for clients based on the results of the clients’ suitability test and recommended asset allocation; (c) distributing documents for communicating with and
review the information disclosed or disseminated regularly or every time there is a change or an update so that the information is current. Clause 17 Securities clearing houses and central securities
;Network Security) 5. การควบคุมการพัฒนา หรือแก้ไขเปลี่ยนแปลงระบบงานคอมพิวเตอร์ (Change Management) 6. การสำรองข้อมูลและระบบ